Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.62 |
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285480 | 0.90 | HDAC1 (0.57) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL8284504 | 0.90 | HDAC1 (0.57) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL7365012 | 0.86 | HDAC1 (0.76) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL15480412 | 0.86 | LTA4H (0.74) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL8272483 | 0.84 | LTA4H (0.58) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL8271090 | 0.84 | HDAC1 (0.67) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL832694 | 0.84 | LTA4H (0.65) | LTA4HSENP1RAB9A | |
| SCHEMBL23283414 | 0.82 | LTA4H (0.62) | LTA4HSENP1RAB9A | |
| SCHEMBL5999222 | 0.81 | LTA4H (0.52) | HDAC1HDAC6HDAC2HDAC11HDAC8 | |
| SCHEMBL9724937 | 0.81 | LTA4H (0.61) | LTA4HSENP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150056191-A1 | IGF1 BIOMARKER FOR IGF1R INHIBITOR THERAPY | MERCK SHARP & DOHME CORP. | 2015-02-26 | — | — | US | disclosed |
| US-20140079665-A1 | THERAPEUTIC ANTI-IGF1R COMBINATIONS | MERCK SHARP & DOHME CORP. | 2014-03-20 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2405270-B1 | IGFBP2-Biomarker | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2405270-A1 | IGFBP2-Biomarker | Schering Corporation (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011057064-A1 | IGF1R INHIBITOR BASED TREATMENT OF PROSTATE CANCER | LONG BRIAN (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| WO-2010124009-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009055343-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009005673-A1 | ANTI-IGF1R | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008156613-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | HDAC1 1207/4885HDAC6 1580/4885HDAC2 639/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | HDAC1 2097/4885HDAC6 3567/4885HDAC2 3773/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | HDAC1 1207/4885HDAC6 1580/4885HDAC2 639/4885 |
| US-20150056191-A1 | IGF1 BIOMARKER FOR IGF1R INHIBITOR THERAPY | IGF1R, IGFBP1, IGF2BP2 | HDAC1 1120/4885HDAC6 3085/4885HDAC2 2338/4885 |
| US-20140079665-A1 | THERAPEUTIC ANTI-IGF1R COMBINATIONS | IGF1R, IGFBP1, IGFBP3 | HDAC1 849/4885HDAC6 653/4885HDAC2 2280/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | HDAC1 2006/4885HDAC6 1868/4885HDAC2 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.